Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
GLA
mutations following 6 months of migalastat treatment
Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable
GLA
mutations following 6 months of migalastat treatment
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started